Navigation Links
Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals
Date:6/12/2008

the JV, Synovics will also have access to substantial resources to build and operate its business well beyond those available in-house with its current stage of development."

"The Company and I in particular, have great enthusiasm for the alliance with Maneesh. We believe that it represents a significant competitive advantage and potentially great value in a generic market where achieving lowest costs is critical and the driving force for growth. Vinay Sapte, the Managing Director of Maneesh, has demonstrated his keen ability to grow a pharmaceutical organization with his performance in building Maneesh over the past several years. The Company is most fortunate to have Mr. Sapte and other new members of Maneesh on its board together with Harry Singh."

Mr. Sapte commented, "Our zeal for Synovics is obvious by the investment we have made. We have also made Maneesh resources of personnel, operating systems and facility utilization available to the Company and presently have people from both organizations meeting in the US and India. This is in addition to the plan of providing value engineered low-cost manufacturing, product development and regulatory filings for generic drug approvals by the US Food and Drug Administration. We believe we can have an immediate and important impact on the operation of the Company and assist it in accelerating its growth."

About Maneesh:

Maneesh is one of the fastest growing pharmaceutical companies in India. With its headquarters in Mumbai, the financial capital of India, Maneesh is a combination of high quality low-cost manufacturing, product development and international marketing. Maneesh ranks in the top 50 manufacturing companies in the Indian market of more than 8000 companies and is rapidly expanding globally through joint ventures and subsidiaries in more than 70 countries across Africa, South America, Europe, Middle East, and the Asian Continents. Maneesh has a strong marketing presence in its two I
'/>"/>

SOURCE Synovics Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Casual, no-strings sexual encounters are increasingly common on ... than others to "hook up"? A new study ... Behavioral and Preventive Medicine, published online by the ... are certain factors and behaviors associated with sexual ... "Given the potential for negative emotional and physical ...
(Date:6/19/2013)... block the body,s system for repairing damage to the ... unlikely as it may seem, those compounds are sparking ... driven by a mutation in BRCA, a gene that ... the mutation. The compounds, termed PARP inhibitors, are the ... of Chemical & Engineering News . C&EN is ...
(Date:6/19/2013)... at Moffitt Cancer Center and colleagues at Louisiana State ... cancers that require immediate therapy. It relies on understanding ... goal is to better predict a prostate cancer,s aggressiveness ... was published in the online journal PLOS ONE ... cancer accounts for 20 percent of all cancers and ...
(Date:6/19/2013)... 19, 2013 Alternatives, a revolutionary new ... to quit using drugs while allowing them to continue ... founders of Alternatives, believe that abstinence-only approaches force people ... treatment and that this approach hurts instead of helping. ... the United States need treatment for addiction but only ...
(Date:6/19/2013)... Many trying-to-conceive couples seek medical ... according to a recent study published ... results of this research confirm what Fairhaven Health ... – that trying-to-conceive women would benefit from tracking ... weight. Fairhaven Health is a leading provider of ...
Breaking Medicine News(10 mins):Health News:Why are some college students more likely to 'hook up'? 2Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4
... choosing a partner, women believe the lower the man,s voice, ... a woman with a higher voice is more likely to ... the latest edition of the online journal Evolutionary Psychology ... pitch and perceived infidelity and offers insight into the evolution ...
... Osteoarthritis - the most influential European bone meeting ... ,Palacio de Congresos, from March 23-26, 2011:,Register before ... of lower registration fees. Listen to ... Learn about key topics in 12 Meet-the-Professor Sessions, Take ...
... The combined effects of chemotherapy and endocrine therapy ... cancer survivors. In a study scheduled for publication in ... Medicine and Rehabilitation , researchers from the Oregon Health ... breast cancer survivors whether they had fallen in the ...
... HealthDay Reporter , THURSDAY, March 3 (HealthDay News) -- More ... than men are engaging in same-sex encounters, according to a ... In statistics compiled from interviews with 13,500 men and women ... Growth also indicates that more than half of young people ...
... (HealthDay News) -- Bunions, a common but painful deformity of the ... a new study has found. And the more severe the ... other parts of the body, leading to declines in both general ... is a bump that develops on the side of the big ...
... March 3, 2011 Unexpected results from a Scripps ... ideas about Alzheimer,s diseasepointing to the liver instead of the ... as brain plaques associated with this devastating condition. The findings ... treatment. The study was published online today in ...
Cached Medicine News:Health News:Can you predict your mate will cheat by their voice? 2Health News:Breast cancer survivors at higher risk for falls 2Health News:More Young People Delay Sex, Try Oral Sex First, CDC Says 2Health News:More Young People Delay Sex, Try Oral Sex First, CDC Says 3Health News:Scripps Research study points to liver, not brain, as origin of Alzheimer's plaques 2Health News:Scripps Research study points to liver, not brain, as origin of Alzheimer's plaques 3Health News:Scripps Research study points to liver, not brain, as origin of Alzheimer's plaques 4
(Date:6/19/2013)... , June 19, 2013 The Physician-Patient Alliance for ... fatigue. The need to urgently address this issue ... Sentinel Event Alert #50 , "Medical device alarm safety in ... between January 2008 and June 2012, there were 98 alarm ... in death (82%) , 13 resulted in permanent loss ...
(Date:6/19/2013)... June 19, 2013   Voices Against Brain Cancer ... cure for brain cancer, today announced that it has ... support the clinical investigation of Toca 511 & Toca ... glioma brain cancer (Grade 3 or Grade 4).  Tocagen ... for advanced cancer, with an initial focus on brain ...
(Date:6/19/2013)... 2013   Nektar Therapeutics (Nasdaq: NKTR ... liability (HAL) study for NKTR-181, a first-in-class, opioid ... brain.  This slow rate of entry is designed to reduce ... addiction to current opioid analgesics. 1 In the study ... to placebo in "drug liking" and "feeling high" scores and ...
Breaking Medicine Technology:Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9
... JUNCTION, N.J., Nov. 14, 2011 Insmed Incorporated (Nasdaq CM: ... and CEO of Insmed, will be presenting a corporate overview ... Wednesday, November 16, 2011, at 8:30 AM ET, in New ... available on Insmed,s website, http://www.insmed.com .  The webcast will ...
... N.J., Nov. 14, 2011 Soligenix, Inc. (OTCBB: SNGX) ... announced today its financial results for the third quarter ... third quarter of 2011 were approximately $5,796,000 as compared ... increase in revenues was a result of a $5 ...
Cached Medicine Technology:Insmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference 2Soligenix Reports Third Quarter 2011 Financial Results 2Soligenix Reports Third Quarter 2011 Financial Results 3Soligenix Reports Third Quarter 2011 Financial Results 4Soligenix Reports Third Quarter 2011 Financial Results 5
PremierEdge Stab Knives - 30....
... for the total eye. Whether used ... mode or set independently to accommodate ... settings are adjustable to accommodate maximizing ... for use with tonometer-mounted, hand-held and ...
PremierEdge™ MVR Knives. Angled....
VISCO SHIELD Viscoelastic. Complete with 23g x 7/8" Thin Wall Cannula....
Medicine Products: